Recently, ruxolitinib (RUX), an oral selective JAK1/2 inhibitor, has shown great promise in mouse models of primary and secondary MAS, including improvements in central nervous system involvement [7-9]. This evidence concerns the gene JAK1 and macrophage activation syndrome.